Philip Rawlins2025-04-07T09:00:00
GPCRs are crucial drug targets, but their complex structures present significant challenges in drug discovery. In this article, Domainex’s Philip Rawlins explores how fragment-based screening and innovative technologies like PoLiPa are helping to overcome these hurdles, with a focus on the Adenosine A2a receptor.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-08-20T08:43:00Z
Author Dr Daniel Tillett
2026-07-21T09:36:00
Contributor Jayson Uffens, Drug Target Review
2026-08-20T08:43:00
Author Dr Daniel Tillett
2026-06-15T07:00:00
Contributor Professor Dipak Ramji, Drug Target Review
2023-05-18T10:39:07
Sponsored by BPS Bioscience
2025-10-22T14:00:00
Sponsored by Wuxi Biologics
Site powered by Webvision Cloud